Hope for hepatitis c relapsers: new Triple-Drug combo shows promise
NCT ID NCT01466192
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called MP-424 (telaprevir) added to standard therapy (peginterferon and ribavirin) for people with genotype 2 hepatitis C whose infection came back after previous treatment. The goal was to see if the combination could clear the virus for good. The trial enrolled 108 adults and measured whether the virus stayed undetectable 24 weeks after treatment ended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Telaprevir (MP-424) combined with peginterferon alfa-2b and ribavirin
- What this could lead to
- If successful, this combination could offer a more effective retreatment option for people with genotype 2 hepatitis C who relapsed after previous therapy, potentially leading to higher cure rates.
- What could go wrong
- This is a completed Phase 3 trial with 108 participants, so results are available but may not apply to all patients. Side effects from the drug combination (e.g., anemia, rash) are possible, and the regimen is intensive with multiple drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Toranomon Hospital
Minato-ku, Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a cholesterol drug and a bile acid pill help reverse liver scarring?
- Massive study aims to map hepatitis c elimination in pakistan
- Can a blood pressure drug reverse liver damage in hepatitis c?
- New hepatitis c drug combo shows promise in early trial
- New study tests faster hepatitis c detection for drug users
- New hope: hepatitis c drugs after liver cancer treatment